Epidermal growth factor receptor mutant form (EGFR (mutant))

Epidermal growth factor receptor mutant forms refer to variants of the human epidermal growth factor receptor gene that harbor activating mutations. These are most commonly found in non-small cell lung cancer but also occur in other cancers. The most frequent mutations include deletions in exon 19 and point mutations such as L858R in exon 21; these changes lead to constitutive activation of the tyrosine kinase domain even without ligand binding. This results in persistent stimulation of downstream signaling pathways controlling cell proliferation and survival—driving oncogenesis. Mutant forms often show increased dimerization independent of ligand presence compared with wild-type receptors[3]. Targeted therapies have been developed specifically for these mutants due to their central role in tumor biology; however, resistance frequently emerges through secondary mutations or alternative pathway activation. Testing for specific EGFR mutations is now standard practice for patient selection and treatment planning in NSCLC[2][6][8].

Other names

Mutant EGFREGFR mutantErbB1 mutantHER1 mutantMutated epidermal growth factor receptor

Inhibition of tyrosine kinase activity to block downstream signaling pathways that drive cell proliferation and survival[8][2]. Small molecule inhibitors bind the ATP-binding site of the mutated kinase domain. Monoclonal antibodies block ligand binding or promote immune-mediated destruction.